Based on the key indicators related to Keros Therapeutics' liquidity, profitability, solvency, and operating efficiency, Keros Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At this time, Keros Therapeutics' Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 3.7 M in 2025, whereas Net Tangible Assets are likely to drop slightly above 166.3 M in 2025. Key indicators impacting Keros Therapeutics' financial strength include:
The financial analysis of Keros Therapeutics is a critical element in measuring its lifeblood. Investors should not minimize Keros Therapeutics' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Please note, the imprecision that can be found in Keros Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Keros Therapeutics. Check Keros Therapeutics' Beneish M Score to see the likelihood of Keros Therapeutics' management manipulating its earnings.
Keros Therapeutics Stock Summary
Keros Therapeutics competes with Ideaya Biosciences, AnaptysBio, MeiraGTx Holdings, Janux Therapeutics, and Fennec Pharmaceuticals. Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Keros Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 97 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what Keros Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Keros Therapeutics's current stock value. Our valuation model uses many indicators to compare Keros Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Keros Therapeutics competition to find correlations between indicators driving Keros Therapeutics's intrinsic value. More Info.
Keros Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Keros Therapeutics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Keros Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Keros Therapeutics Systematic Risk
Keros Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Keros Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was five with a total number of output elements of fifty-six. The Beta measures systematic risk based on how returns on Keros Therapeutics correlated with the market. If Beta is less than 0 Keros Therapeutics generally moves in the opposite direction as compared to the market. If Keros Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Keros Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Keros Therapeutics is generally in the same direction as the market. If Beta > 1 Keros Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Keros Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Keros Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Keros Therapeutics growth as a starting point in their analysis.
Keros Therapeutics March 22, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Keros Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Keros Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Keros Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Keros Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Keros Therapeutics's daily price indicators and compare them against related drivers.
When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.